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'Department ofPaediatrics, Free University Hospital, De Boelelaan 1117, 1081 HV Amsterdam; 2Dutch Childhood Leukemia
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Summary In vitro drug sensitivity of leukaemic cells might be influenced by the contamination of such a
sample with non-malignant cells and the sample source. To study this, sensitivity of normal peripheral blood
(PB) lymphocytes to a number of cytostatic drugs was assessed with the MTT assay. We compared this
sensitivity with the drug sensitivity of leukaemic cells of 38 children with acute lymphoblastic leukaemia. We
also studied a possible differential sensitivity of leukaemic cells from bone marrow (BM) and PB. The
following drugs were used: Prednisolone, dexamethasone, 6-mercaptopurine, 6-thioguanine, cytosine arabino-
side, vincristine, vindesine, daunorubicin, doxorubicin, mafosfamide (Maf), 4-hydroperoxy-ifosfamide, tenipo-
side, mitoxantrone, L-asparaginase, methotrexate and mustine.
Normal PB lymphocytes were significantly more resistant to all drugs tested, except to Maf. Leukaemic BM
and PB cells from 38 patients (unpaired samples) showed no significant differences in sensitivity to any of the
drugs. Moreover, in 11 of 12 children with acute leukaemia of whom we investigated simultaneously obtained
BM and PB (paired samples), their leukaemic BM and PB cells showed comparable drug sensitivity profiles. In
one patient the BM cells were more sensitive to most drugs than those from the PB, but the actual differences
in sensitivity were small.
We conclude that the contamination of a leukaemic sample with normal PB lymphocytes will influence the
results of the MTT assay. The source of the leukaemic sample, BM or PB, does not significantly influence the
assay results.
Differences in sensitivity to cytostatic drugs between normal
and malignant cells are important for a number of reasons.
In the first place, the clinical use of drugs with a preferential
toxicity towards malignant cells is preferred. Secondly, the
success of pharmacologic bone marrow (BM) purging of
malignant cells before autologous BM transplantation, cur-
rently intensively studied and practised (Kluin-Nelemans et
al., 1984; Rizzoli et al., 1990; Scholzel et al., 1986; Singer &
Linch, 1987), depends on malignant cells being more sensitive
to the drugs applied than normal haematopoietic stem cells.
Finally, one should know the drug sensitivity of normal cells,
to determine the influence of their presence in a malignant
tumour sample of which in vitro drug sensitivity is assessed.
A tetrazolium-based assay to study in vitro antitumour
activity ofcytostatic drugs was described almost 40 years ago
(Black & Speer, 1953). A similar assay is the MTT assay, in
the English literature first described by Mosmann (1983). The
MTT assay is a valulable drug sensitivity assay (Veerman &
Pieters, 1990). In this assay no distinction can be made
between different kinds of living cells in the sample tested
(Pieters et al., 1988). Therefore, the presence of a substantial
number of normal cells might influence the results (Kirkpat-
rick et al., 1990).
In studies of drug resistance in leukaemic patients, both
BM and peripheral blood (PB) samples are investigated.
Prior to the collective evaluation of the results, one should
rule out the possibility that BM and PB leukaemic cells differ
in drug sensitivity. Therefore, we determined and compared
the in vitro sensitivity of normal PB lymphocytes and leu-
kaemic cells from BM and PB of children with acute leukae-
mia to 16 cytostatic drugs.
Materials and methods
Reagents
Prednisolone disodiumphosphate (PRD), dexamethasone di-
sodiumphosphate (DXM), daunorubicin (DNR), L-aspara-
ginase (L-Asp), mustine hydrochloride (Must), cytosine
arabinoside (Ara-C), vindesine (VDS), vincristine (VCR),
mitoxantrone (Mitox), methotrexate (MTX), and teniposide
(Teni) were obtained from our hospital pharmacy, together
with acidified (0.04 N HCI) isopropanol; 6-thioguanine (6-
TG), 6-mercaptopurine (6-MP), and doxorubicin (Dox) from
Sigma; mafosfamide (Maf, 4-hydroxycyclofosfamide) and 4-
hydroperoxy-ifosfamide (4-HI), active derivatives ofcyclofos-
famide (CFM) and ifosfamide (IFM) respectively, were kind-
ly provided by ASTA Pharma AG (Dr M. Peukert, Bielefeld,
Germany).
PRD (of which 75% corresponds to pure prednisolone)
was dissolved in saline. DNR, L-Asp, Must, VDS, and Dox
were dissolved in distilled water, 6-MP and 6-TG in 0.1 N
NaOH, Maf in PBS, and 4-HI in DMSO/distilled water (1:1).
DXM, Ara-C, VCR, Mitox, MTX and Teni were obtained in
soluble form.
Cells were suspended in RPMI 1640 (Gibco, Dutch modifi-
cation), containing 20% foetal calf serum, 2 mM L-glutamine,
1OOIUml-' penicillin, 100l gml-' streptomycin, 0.125 lg
ml-' fungizone, 200 igmlml gentamycin, all obtained from
Flow Laboratories, and 5 g ml1' insulin, 5 ig ml' trans-
ferrin, and 5 ngml' sodium selenite from Sigma. MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium-bromide)
was obtained from Sigma.
Cells
Normal PB was obtained from 13 healthy adult volunteers.
Mononuclear cells were isolated by density gradient centri-
fugation with Ficoll Isopaque (Lymphoprep; density 1.077 g
ml-'; Nyegaard, Oslo). Immunological phenotyping was
done as described (Veerman et al., 1983). BM and/or PB
samples from 38 children with acute lymphoblastic leukaemia
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Figure 1 Demonstration of the linear relationship between the
number of living normal lymphocytes after 4 days culture and
optical density. Averaged results of the four samples tested are
shown, mean± 1 s.d. Individual r2 values ranged from 0.972 to
0.998.
(ALL) at initial diagnosis were mostly obtained from the
laboratory of the Dutch Childhood Leukemia Study Group.
From 11 of 38 children with ALL and from one child with
acute non-lymphocytic leukaemia (ANLL), paired BM and
PB samples were collected and investigated simultaneously.
The cells were freshly tested.
MTT assay
Storage and preparation of the drug solutions was done as
previously described (Pieters et al., 1990). Eighty ftl cell
suspension - 2 x 106 ml1' in case of leukaemic cells, 1 x 106
ml-' in case of normal cells - was added to the wells of
96-well microculture plates. The optical density (OD) is line-
arily related to the cell number in this range, as described by
Pieters et al. for ALL cells (1990), and as shown in Figure 1
for normal PB lymphocytes. In the wells, 20yl of the various
drug solutions was dispensed already. Each drug was tested
in six concentrations, in duplicate (Table I). Because we
observed evaporation in the outer wells, these were filled with
RPMI. Six wells containing medium only were used for
blanking the reader, another six wells containing cells and
medium were used to determine the control cell survival. The
plates were incubated in humidified air containing 5% CO2
for 4 days at 37°C. Then 10 gl MTT solution (5 mgml-')
was added and after shaking the plates until the cell pellet
was dissolved, they were incubated for 6 h. The formed
formazan crystals were dissolved with 100jil isopropanol.
The OD of the wells was determined with a microplate
spectrophotometer (Titertek Multiskan MCC 340) at 565 nm.
The cell survival (CS) was calculated by the equation:
CS = (OD treated well/mean OD control wells) x 100%. The
LC_,O the drug concentration required to kill 50% of the cells
as compared to the control cell survival was calculated from
the dose-response curve.
Statistics
The chi-squared test with Yates' correction and the Wil-
coxon's ranking test for unpaired data were used to two-
tailed testing at a level of significance of 0.05.
Results
There were 28 B-lineage and ten T-ALL cases, and one
ANLL case. All samples contained more than 80% blasts.
The differences in blast percentages between leukaemic BM
and PB samples were small, for the paired samples 93.1 ± 5.8
(mean ± s.d.) and 88.3 ± 7.8 respectively, for the unpaired
samples 93.4 ± 6.0 and 92.9 ± 3.5 respectively. The normal
PB samples contained 19% (median, range 4-38) monocytes
after isolation at day 0, and 10% (0-21) at the end of the
4-days incubation period. The remaining cells were almost
entirely lymphocytes. This relative decrease in monocytes was
not caused by adherence of these cells to the walls of our
polystyrene plates. The percentage of monocytes at day 0 did
not correlate with sensitivity to any of the drugs (data not
shown). The median T/B cell ratio as determined by the
CD2+/CD19+ cell ratio, was 10.0 (range 3.5-45.5) before,
and 18.0 (8.0-92.0) after the incubation period, indicating a
selective decrease of B-lymphocytes. The median CD4+/
CD8+ cell ratio was 1.3 (range 0.4-3.0) before, and 1.4
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Table I Drugs, concentration ranges and dilution steps for in vitro
drug sensitivity testing of normal peripheral blood lymphocytes and
childhood leukaemic cells using the MTT assay
Concentration range
Drug (jigml') Dilution step
Prednisolone (PRD) 0.08-250 5
Dexamethasonea (DXM) 0.0003-0.8 5
6-Mercaptopurine (6-MP) 15.6-500 2
6-Thioguanine (6-TG) 1.56-50 2
Cytosine Arabinoside (Ara-C) 0.002-2.5 4
Vincristine (VCR) 0.05-50 4
Vindesine (VDS) 0.05-50 4
Daunorubicin (DNR) 0.002-2 4
Doxorubicin (Dox) 0.001-1 4
Teniposide (Teni) 0.003-8 5
Mafosfamide (Maf) 0.10-100 4
4-Hydroperoxy-Ifosfamide (4-HI) 0.10-100 4
Mustine (Must) 0.16-500 5
L-Asparaginase (L-Asp) 0.003- 1Ob 5
Mitoxantrone (Mitox) 0.001-1 4
aPartofthesampleswastestedwithaconcentration rangeof0.0006to
2,jgml-I; b IUml-'.
Daunorubicin
I0) 0-
n)
0.002 0.080.031 05 2
Concentration (,ug ml-')
Figure 2 Dose-response curves for two representative drugs,
VCR and DNR, calculated from individual curves (numbers in
parentheses) of leukaemic and normal samples. Shown are the
mean cell survivals (CS) + 1 standard deviation. Vincristine:
_, Leukaemic samples (23); M, Normal samples (12). Dau-
norubicin: , Leukaemic samples (20); E, Normal samples
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(range 0.3-2.6) after the incubation. Normal lymphocytes
reduced more MTT per living cell at day 4 than ALL cells:
OD of 0.381/105 cells (mean, four samples) vs 0.210/10' cells
(n = 15) respectively. Mean control cell survival at day 4 of
normal lymphocytes (n =4) was 78% (range 47-99%) vs
67% (23-127%) of ALL cells (n = 15). Neither significant
proliferation nor transformation (to normal lymphoblasts) of
normal lymphocytes was observed.
The mean control OD reading in case of normal samples
was 0.192 (range 0.090-0.300), and for the ALL samples
0.167 (0.59-0.496). Both for normal lymphocytes and leu-
kaemic cells dose-response curves were found for all drugs,
except for MTX. We did not further evaluate the results
obtained with MTX. Average dose-respnse curves were cal-
culated, based on all individual curves, for the normal and
leukaemic samples. Data for two representative drugs, VCR
and DNR, are shown in Figure 2. For each drug the mean
CS values of the leukaemic cells were lower than the CS
values of the normal PB lymphocytes, i.e., the leukaemic cells
were more sensitive. However, an overlap in the ranges of CS
values existed (Figure 2). The CS values of the leukaemic
cells varied to a greater extent than those of the normal PB
lymphocytes. Leukaemic cells were significantly more sen-
sitive to each drug evaluable, except to Maf, than normal PB
lymphocytes (Table II). These differences retained a similar
significance when only PB leukaemic cells were compared
with normal PB lymphocytes, with exception of Maf (Table
II). To Maf the PB leukaemic cells showed a significantly
greater sensitivity than the normal cells, because the PB
leukaemic cells tended (P close to 0.1) to be more sensitive to
Maf than the BM leukaemic cells. Using the LC70 (concentra-
tion lethan to 70% of the cells), PB leukaemic cells still
showed a higher sensitivity to Maf, but the tendency dimin-
ished (P 0.25). Thus, normal PB lymphocytes were signifi-
cantly less sensitive than leukaemic cells from BM and PB to
TableIII Drugsensitivity ofchildhoodacutelymphoblasticleukaemic
cells from bone marrow (BM) and peripheral blood (PB)
LC50 values in figml', median (range)
BM samples PB samples P-valuer
(n = 17-24)a (n = 11-18)b
Prednisolone 23.8
(<0.08->250)
Dexamethasone 0.011
(<0.0003->0.8)
6-Mercaptopurine 145.0
(<15.6->500)
6-Thioguanine 7.1
(1.7->50)
Cytosine arabinoside 0.44
(<0.002->2.5)
Vincristine 2.5
(<0.05->50)
Vindesine 2.4
(0.15->50)
Daunorubicin 0.08
(0.003->2)
Doxorubicin 0.50
(0.083->1)
Teniposide 0.26
(0.058->8)
Mafosfamide 8.8
(1->100)
4-Hydroperoxy-ifosfamide 10.0
(1.9-29.2)
L-Asparaginased 0.36
(<0.003->10)
Mitoxantrone 0.067
(0.011->1)
3.3
(<0.08->250)
0.027
(>0.0003->0.8)
125.0
(<15.6->500)
6.8
(3.5->50)
0.51
(<0.002-0.72)
2.4
(<0.05-44.2)
2.3
(0.4->50)
0.13
(>0.002-0.72)
0.58
(0.093->1)
0.35
(0.057-2.027)
4.0
(0.2-39.4)
5.1
(0.2-15.6)
0.21
(<0.003->10)
0.050
(<0.001-0.7)
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
"4-Hydroperoxy-ifosfamide ninesamples;b4-hydroperoxy-ifosfamide and
doxorubicineightsamples;cWilcoxon'srankingtestforunpaireddata;ns:not
significant (P>0.05); dIU ml1'.
Table H Drug sensitivity ofnormal peripheral blood lymphocytes and childhood acute lympho-
blastic leukaemic (ALL) cells
LC50 values," 1tgml-':
median (range) P-values'
Normal Leukaemic Normal vs
samples samples BM+PB ALL Normal vs PB
(n = 11-13) (n =22-30)' samples ALL samples
Prednisolone 250 1.84 <0.05 <0.05
(1.58->250) (<0.08->250)
Dexamethasone >0.8 0.029 <0.01 <0.01
(0.019->0.8) (<0.0003->0.8)
6-Mercaptopurine 410.7 125 <0.01 <0.01
(125->500) (<15.6->500)
6-Thioguanine 46.9 6.6 <0.01 <0.01
(20.2->50) (2.7->50)
Cytosine arabinoside >2.5 0.469 <0.01 <0.01
(0.501->2.5) (<0.002->2.5)
Vincristine 37.2 2.57 <0.01 <0.01
(8.2->50) (<0.05->50)
Vindesine 41 2.6 <0.01 <0.01
(4.1->50) (0.15->50)
Daunorubicin 1.112 0.092 <0.01 <0.01
(0.435->2) (<0.002->2)
Doxorubicin >1 0.5 <0.01 <0.05
(0.48->1) (0.08->1)
Teniposide 1.493 0.263 <0.01 <0.01
(0.77-6.58) (0.06->8)
Mafosfamide 16.2 6.6 0.16 <0.05
(3.2->100) (0.2->100)
4-Hydroperoxy-ifosfamide not done 5.4
(0.23-29.2)
L-Asparaginased >10 0.19 <0.01 <0.01
(1.26->10) (<0.003->10)
Mitoxantrone 0.839 0.055 <0.01 <0.01
(0.14->1) (0.001->1)
aLethal concentration to 50% ofthe cells;b4-hydroperoxy-ifosfamide used in 13 samples; Paired
samples: only PB samples included; cWilcoxon's ranking test for unpaired data; dIUml- l.472 G.J.L. KASPERS et al.
PRD, DXM, 6-MP, 6-TG, VCR, DNR, Ara-C, VDS, Teni,
L-Asp, Mitox and Dox.
We compared the range and median LC50 values of each
drug for all leukaemic BM samples and all leukaemic
PB samples from 38 ALL patients. No significant differences
were found between BM and PB leukaemic cells in sensitivity
to any of the drugs (Table III). In 12 cases (11 ALL,
1 ANLL) drug sensitivity results from paired BM and PB
samples were studied. Analysis of these paired data also
showed no preferential sensitivity of BM or PB leukaemic
cells to any of the drugs. Evaluating the individual data,
11 of the 12 patients showed no differences in drug sensitivity
between their BM and PB leukaemic cells. One child with
ALL showed a greater sensitivity of the BM cells. Although
statistically significant, the actual differences in LC50 values
were small. There was a good correlation between the paired
BM and PB LC50 values in most individual cases and in
the 106 paired BM and PB LCm comparisons together
(Figure 3).
Discussion
Several studies have compared the drug sensitivity of non-
malignant and leukaemic cells. Table IV summarises the
results of the studies in which patient samples were investi-
gated. This table shows that in most studies non-malignant
cells were found to be less sensitive to the drugs used than
leukaemic cells. Occasionally, a greater sensitivity of the non-
malignant cells was found (Scholzel et al., 1986). For some
drugs (e.g. DNR and Dox) the results are contradictory. This
Table IV Summary ofrelevant literature regarding in vitro drug sensitivity ofhuman normal haemotopoetic cells vs human leukaemic
cells
Sensitive
Less Equally More
Reference Cells Assay Drugs (compared to normal cells)
Gall etal. (1980) ALL, CLL, AML and Viable cell count Cortisol AML/CML ALL/CLL
CML vs normal BM and
Spiro et al. (1981a,b)
Speth et al. (1988)
Singer et al. (1987)
Schrek et al. (1967)
Schrek
(1961, 1964)
Scholzel et al (1986)
Kluin-Nelmans
et al. (1984)
Jayaram et al. (1986)
Greenberg et al. (1976)
Buick et al. (1979)
Asselin et al. (1989)
Weisenthal et al. (1987)
Taetle et al. (1983)
PB ly's
CML-CFC vs
nonnal BM- and
PB-CFC
ANLL BM vs
nonnal BM
progenitor
AML-CFC (PB) vs
normal GM-CFC
CLL (PB) vs
normal PBL
CLL and LS vs
normal PBL
AML-CFC vs
normal BM CFC-E
and -M
L-CFC vs normal
CFC-GM and BFU-E
Clonogenic
Clonogenic
Clonogenic
Viable cell count
Viable cell count
Clonogenic
Clonogenic
ANLL and ALL vs nor- Depression of[GTP]
mal BM leukocytes
L-CFC vs normal Clonogenic
granulocytic CFC
AML-CFC vs Colony
nonnal granulopoetic and
T-ly CFC
ALL BM vs normal BM Viable cell count
mononuclear
ALL and CLL vs DiSC
normal PBL
(B-)CLL-CFC vs Clonogenic
nonnal T-PBL
Dox, DNR, L-
Asp, Bs, Ara-C,
HU, Mel, 6-TG
m-AMSA
Dox
Maf, Mel, Ara-C,
4-HC, VP-16
L-Asp
Cortisol, PRD
Mitox, DNR
4-dmDNR,
4'doDox
Maf
CML CML
(other drugs) (AraC)
ANLL
AML
CLL
CLL/LS
AML
L-CFC
Tiazofurin ANLL/ALL
Ara-C, 6-TG
Dox, DNR
L-Asp
VCR
HC, 5-FU, Mel,
MTX, Dox, Blm,
CA, CP, Ara-C
L-CFC L-CFC
(6-TG) (AraC)
AML
ALL
ALL/CLL
CLL CLL
(Blm) (other drugs)
Werthamer et al. (1971)
Verdonck et al. (1990)
Katano et al. (1989)
Potter et al. (1980)
CLL vs normal RNA and protein
PB ly's precursor
incorporation
AML-, ALL- and CMF- Clonogenic
CFC vs
normal BM CFC-GM
and -GEMM
ALL BM vs normal BM Bromodeoxy- uridine
mononculear incorporation in S-
phase cells
AML BM vs nonnal BM3H Thymidine
incorporation
Cortisol
MTX not evaluable
CLL
alkyllysophos-
pholipid
Ara-C
AML/ALL/
CML
ALL
Ara-C AML
AML: acute myeloid leukaemia; BFU-E: bloodformingunits-eryhroid; Blm: bleomycine; Bs: busulfan; CA:chlorambucil; CFC: colony
forming cells; CFC-E: CFC-erythroid; CFC-GEMM: CFC ul macrophage- megkaryocte; CFC-GM: CFC-
granulocytic-myeloid; CFC-M: CFC-myeloid; CLL: chronic lymphocytic leukaenia; CML: chronic myeloid leukaemia; CP: cisplatinum;
4-dmDNR: 4-demethyoxy DNR; 4'doDox: 4'deoxyDox; 5-FU: 5-fluorouracil; GTP: guanyl triphosphate; HC: hydrocortisone; 4-HC:
4-hydroperoxycyclofosfamide; HU:Hydroxy-ureum; L-CFC:leukaemic-CFC; LS:lymphosarcomainleukaemicphase;ly:lymphocyte;Mel:
melphalan; MTX: methotrexate. Other abbreviations: See Table I and text.DRUG SENSITIVITY OF NORMAL AND LEUKAEMIC LYMPHOCYTES 473
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Figure 3 Comparison of in vitro drug sensitivity between
(paired) BM and PB leukaemic cells from 12 patients. Each point
represents a paired LC50 value (n = 106). The line shown is the
line x = y.
might be explained by the differences in assays, drug concen-
trations and cells used.
We demonstrated, using the MTT assay, that normal PB
lymphocytes are significantly more resistant to PRD, DXM,
6-MP, 6-TG, VCR, DNR, Ara-C, VDS, Teni, L-Asp, Mitox
and Dox than leukaemic cells of children with ALL, also
when only leukaemic samples from the PB were evaluated
(Table II). We did not find a significantly greater sensitivity
of the BM and PB leukaemic cells to Maf (an active metabo-
lite of CFM), in accordance with the results of Kluin-
Nelemans et al. (1984) and Singer and Linch (1987). In two
out of three studies using melphalan, another alkylating
agent, again an equal sensitivity of non-malignant and leu-
kaemic cells was reported (Spiro et al., 1981a; Singer &
Linch, 1987). These observations suggest that alkylating
agents have a less favourable therapeutic index. Their value
in BM purging - based on direct cytotoxic activity - seems to
be small. This does not necessarily implicate that these drugs
are not useful in this respect. Recently, Rizzoli et al. (1990)
reported a beneficial effect of BM puring with Maf (in indivi-
dually adjusted doses) on leukaemic free survival after auto-
logous-purged - BM transplantation and suggested this could
be due to activation of immunological systems able to con-
trol minimal residual disease in vivo, and not primarily to the
direct cytotoxic activity of the drug during the purging proce-
dure. The wide range of drug sensitivity of leukaemic cells
from different patients, implies the necessity of individually
adjusted doses of cytostatic drugs for optimal BM purging,
as indeed has been reported to be more successful than
standard purging (Rizzoli et al., 1990).
The cause(s) of the presented differential drug sensitivity of
normal lymphocytes and leukaemic cells are largely un-
known. However, these cells differ in several aspects, like
immunophenotype and differentiation-stage. Normal PB lym-
phocytes are mainly of the T-lineage (which was even more
accentuated after the 4-days incubation period of the MTT
assay in the present study) and represent mature cells. Most
childhood actue leukaemias are of the immature B-lineage
phenotype, as was the case in this study. The T-lineage
leukaemias show a less mature phenotype than normal T-
cells. Recently we found that T-ALL cells were relatively
resistant to various drugs compared to immature B-ALL cells
(Pieters et al., in press). Therefore, the differences regarding
immunophenotype between the tested leukaemic and normal
lymphocytes could well contribute to the presented differ-
ences in drug sensitivity. Changes in immunophenotype of
normal lymphocytes might occur in patients suffering a
malignancy. However, we found that the removal of normal
T-lymphocytes from ALL samples with less than 80% ALL
cells resulted in increased drug sensitivity (unpublished data).
This supports the conclusions of the present study. An exten-
sive discussion of all other possible causes of the presented
difference in drug sensitivity is beyond the scope of this
report.
The analysis of the assay results obtained with (unpaired)
BM and PB leukaemic cells from all 38 ALL patients did not
reveal a preferential sensitivity of the PB or BM leukaemic
cells to any of the drugs (Table III). Similarly, no preferential
sensitivity of the (paired) BM or PB leukaemic cells from 12
leukaemic patients (one ANLL, 11 ALL) was found. In 11
out of 12 patients of whom we tested their (paired) BM and
PB leukaemic cells, the sample source did not significantly
influence drug sensitivity. In one case the leukaemic cells
from the BM were significantly more sensitive than those
from the PB, but the actual differences in LCm values were
very small and of no practical importance. The correlation
for all 106 paired BM and PB LC50 comparisons was very
good, with most pairs close to the ideal line x = y (Figure 3).
Our findings agree with those of Bird et al. (1986), who
reported a significant association in sensitivity to a maximum
of six drugs of leukaemic BM and PB cells from 12 patients.
The same was found by Sargent and Taylor (1989) and Spiro
et al. (1981a), in single cases.
We conclude that normal PB lymphocytes are more resis-
tant than childhood ALL cells to a large number of drugs in
vitro. Consequently, the number of normal lymphocytes con-
taminating an ALL sample to be tested should be low, when
the MTT assay or a similar total cell kill assay is used. This
is especially the case in view of the higher survival at day 4
and the higher MTT reduction per living cell of the normal
lymphocytes compared to the untreated ALL cells. The MIT
assay and the Differential Staining Cytotoxicity (DiSC) assay
gave comparable results in samples with 80% (or more)
leukaemic cells, the lowest percentage tested (Pieter et al.,
1989). Therefore, in case of a sample with less than 80%
leukaemic cells, the use of the DiSC assay - in which a
distinction between non-malignant and leukaemic cells can be
made - should be considered. Because this assay is laborious
and subjective, we are investigating techniques to remove
non-malignant cells from leukaemic samples.
Finally, because the drug sensitivity profiles of leukaemic
cells from the BM are quite comparable to those from the
PB, it is allowed to evaluate results obtained using samples
from both sources together, which obviously is of practical
importance.
The laboratory of the Dutch Childhood Leukemia Study Group
(DCLSG) provided most of the patient samples. Board members of
the DCLSG are J.P.M. Bokkerink, M.V.A. Bruin, P.J. Van Dijken,
K. Hahlen, W.A., Kamps, E.F. Van Leeuwen, F.A.E. Nabben,
A. Postma, J.A. Rammeloo, I., Risseeuw-Appel, G.A.M. De Vaan,
E. Th. Van't Veer-Korthof, A.J.P. Veerman, F.C. De Waal, M. Van
Weel-Sipman and R.S. Weening.
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